Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
D 121.64 0.51% 0.62
EXAS closed up 0.51 percent on Friday, March 5, 2021, on 1.72 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical EXAS trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.51%
Stochastic Reached Oversold Weakness 0.51%
Older End-of-Day Signals for EXAS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Exact Sciences Corporation Description

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Lab Testing Medical Tests Polyp Inflammatory Bowel Disease Pancreatic Cancer Colorectal Cancer Molecular Diagnostics Cancer Screening Genzyme Diagnostic Gastroenterology Mayo Clinic

Is EXAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 159.54
52 Week Low 35.25
Average Volume 1,743,198
200-Day Moving Average 109.09
50-Day Moving Average 140.11
20-Day Moving Average 140.32
10-Day Moving Average 132.91
Average True Range 8.32
ADX 19.7
+DI 15.84
-DI 41.37
Chandelier Exit (Long, 3 ATRs ) 133.03
Chandelier Exit (Short, 3 ATRs ) 135.09
Upper Bollinger Band 159.41
Lower Bollinger Band 121.24
Percent B (%b) 0.01
BandWidth 27.20
MACD Line -4.27
MACD Signal Line -1.68
MACD Histogram -2.5895
Fundamentals Value
Market Cap 18.3 Billion
Num Shares 150 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -69.00
Price-to-Sales 13.72
Price-to-Book 7.93
PEG Ratio -1.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 140.96
Resistance 3 (R3) 139.27 131.13 137.74
Resistance 2 (R2) 131.13 126.21 131.98 136.67
Resistance 1 (R1) 126.39 123.17 128.76 128.08 135.59
Pivot Point 118.25 118.25 119.44 119.10 118.25
Support 1 (S1) 113.51 113.33 115.88 115.20 107.69
Support 2 (S2) 105.37 110.29 106.22 106.61
Support 3 (S3) 100.63 105.37 105.54
Support 4 (S4) 102.32